These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1052 related articles for article (PubMed ID: 23461426)
21. A prospective trial of a clinical pharmacy intervention in a primary care practice in a capitated payment system. Altavela JL; Jones MK; Ritter M J Manag Care Pharm; 2008; 14(9):831-43. PubMed ID: 19006440 [TBL] [Abstract][Full Text] [Related]
22. Analysis of Glycemic Control of a Pharmacist-Led Medication Management Program in Patients with Type 2 Diabetes. Ko JJ; Lu J; Rascati K; Stock EM; Juan J; Suh K; Kim Y; Tabor PA; Godley PJ J Manag Care Spec Pharm; 2016 Jan; 22(1):32-7. PubMed ID: 27015049 [TBL] [Abstract][Full Text] [Related]
23. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Tilden DP; Mariz S; O'Bryan-Tear G; Bottomley J; Diamantopoulos A Pharmacoeconomics; 2007; 25(1):39-54. PubMed ID: 17192117 [TBL] [Abstract][Full Text] [Related]
24. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands. Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654 [TBL] [Abstract][Full Text] [Related]
25. Bariatric surgery for patients with type 2 diabetes mellitus requiring insulin: Clinical outcome and cost-effectiveness analyses. McGlone ER; Carey I; Veličković V; Chana P; Mahawar K; Batterham RL; Hopkins J; Walton P; Kinsman R; Byrne J; Somers S; Kerrigan D; Menon V; Borg C; Ahmed A; Sgromo B; Cheruvu C; Bano G; Leonard C; Thom H; le Roux CW; Reddy M; Welbourn R; Small P; Khan OA PLoS Med; 2020 Dec; 17(12):e1003228. PubMed ID: 33285553 [TBL] [Abstract][Full Text] [Related]
26. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial. Simpson SH; Lier DA; Majumdar SR; Tsuyuki RT; Lewanczuk RZ; Spooner R; Johnson JA Diabet Med; 2015 Jul; 32(7):899-906. PubMed ID: 25594919 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of a Pharmacist-Managed Diabetes Program in a Primary Care Setting Within an Integrated Health Care System. Benedict AW; Spence MM; Sie JL; Chin HA; Ngo CD; Salmingo JF; Vidaurreta AT; Rashid N J Manag Care Spec Pharm; 2018 Feb; 24(2):114-122. PubMed ID: 29384029 [TBL] [Abstract][Full Text] [Related]
29. Effect of a Pharmacist-Led Program on Improving Outcomes in Patients with Type 2 Diabetes Mellitus from Northern Cyprus: A Randomized Controlled Trial. Korcegez EI; Sancar M; Demirkan K J Manag Care Spec Pharm; 2017 May; 23(5):573-582. PubMed ID: 28448779 [TBL] [Abstract][Full Text] [Related]
30. Effect of Multifactorial Treatment Targets and Relative Importance of Hemoglobin A1c, Blood Pressure, and Low-Density Lipoprotein-Cholesterol on Cardiovascular Diseases in Chinese Primary Care Patients With Type 2 Diabetes Mellitus: A Population-Based Retrospective Cohort Study. Wan EYF; Fung CSC; Yu EYT; Chin WY; Fong DYT; Chan AKC; Lam CLK J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862945 [TBL] [Abstract][Full Text] [Related]
31. Enhancing diabetes care by adding a pharmacist to the primary care team. Ip EJ; Shah BM; Yu J; Chan J; Nguyen LT; Bhatt DC Am J Health Syst Pharm; 2013 May; 70(10):877-86. PubMed ID: 23640349 [TBL] [Abstract][Full Text] [Related]
32. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Palmer MJ; Barnard S; Perel P; Free C Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012675. PubMed ID: 29932455 [TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands. de Vries FM; Denig P; Visser ST; Hak E; Postma MJ Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380 [TBL] [Abstract][Full Text] [Related]
34. Pharmacoeconomic analysis of the diabetes initiative program: a pharmacist-physician collaborative care model. Franklin BE; Farland MZ; Thomas J; McFarland MS; Ray SM; Byrd DC Ann Pharmacother; 2013 Dec; 47(12):1627-34. PubMed ID: 24259610 [TBL] [Abstract][Full Text] [Related]
35. Estimation and Prediction of Avoidable Health Care Costs of Cardiovascular Diseases and Type 2 Diabetes Through Adequate Dairy Food Consumption: A Systematic Review and Micro Simulation Modeling Study. Javanbakht M; Jamshidi AR; Baradaran HR; Mohammadi Z; Mashayekhi A; Shokraneh F; Rezai Hamami M; Yazdani Bakhsh R; Shabaninejad H; Delavari S; Tehrani A Arch Iran Med; 2018 May; 21(5):213-222. PubMed ID: 29738265 [TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Brändle M; Azoulay M; Greiner RA Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624 [TBL] [Abstract][Full Text] [Related]
37. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Gaebler JA; Soto-Campos G; Alperin P; Cohen M; Blickensderfer A; Wintle M; Maggs D; Hoogwerf B; Han J; Pencek R; Peskin B Vasc Health Risk Manag; 2012; 8():255-64. PubMed ID: 22566747 [TBL] [Abstract][Full Text] [Related]